2020 Quadrivalent Influenza Vaccine
Following the Australian Influenza Vaccine Committee (AIVC) meeting on 9 October 2019, it was determined that all quadrivalent influenza vaccines are recommended to contain the following strains:
- an A/Brisbane/02/2018 (H1N1)pdm09-like virus;
- a B/Washington/02/2019-like (B/Victoria lineage) virus;
- an A/South Australia/34/2019 (H3N2)-like virus; and
- a B/Phuket/3073/2013-like (B/Yamagata lineage) virus.
AusHealth Work will be providing Afluria® Quad to clients in the 2020 flu season. Afluria® Quad is an Australian-made vaccine and is manufactured as recommended by the AIVC and World Health Organisation to immunise against the predominant strains anticipated to be circulating in the southern hemisphere in 2020.
This is one of the vaccines to be used by the Australian Government under the National Immunisation Program (NIP). In case of supply concerns, AusHealth has access to alternate suppliers.